Interleukin-2 variants and their fusion proteins
IL-2 mutant proteins with specific mutations and an anti-PD-1 antibody fusion form an immune complex, addressing toxicity and half-life issues, enhancing stability and therapeutic efficacy in IL-2 treatment.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- フォートビタ バイオロジクス(シンガポール)プライベート リミティド
- Filing Date
- 2022-09-21
- Publication Date
- 2026-05-25
AI Technical Summary
Existing IL-2 molecules face challenges such as high toxicity, short half-life, and difficulty in administration due to rapid clearance, leading to severe side effects and frequent dosing requirements, while current mutant proteins have defects in pharmacokinetic and pharmacodynamic properties.
Development of IL-2 mutant proteins with specific mutations at the IL-2Rα and IL-2Rβγ binding interfaces, a shortened B'C loop region, and N-terminus modifications, combined with an IL-2 fusion protein and anti-PD-1 antibody to form an immune complex, enhancing stability and reducing receptor binding.
The immune complex achieves improved pharmacokinetic properties, reduced receptor binding, and enhanced therapeutic efficacy with decreased toxicity, allowing for sustained IL-2 activity and targeted immune response.
Smart Images
Figure 0007864826000039 
Figure 0007864826000040 
Figure 0007864826000041